TCL Archive Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study November 26, 2010
TCL Archive After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant June 11, 2014